drugset
drugset / Trial / NCT02551549

An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects

NCT02551549 ↗

Phase 1 Completed 24 enrolled Cidara Therapeutics Inc.
RandomizedSingle-groupQuadruple-blindTreatment

Summary

A multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of CD101 Injection in Healthy Subjects.

Timeline

Start
2015-09
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rezafungin Other / unclassified — Intravenous

Indications

No indication recorded.